Evolving Role of Circulating Tumor DNA and Emerging Targeted Therapy in Colorectal Cancer

Midhun Malla; Aparna R Parikh

doi:10.1016/j.hoc.2022.02.009

Evolving Role of Circulating Tumor DNA and Emerging Targeted Therapy in Colorectal Cancer

Hematol Oncol Clin North Am. 2022 Jun;36(3):583-601. doi: 10.1016/j.hoc.2022.02.009. Epub 2022 May 13.

Authors

Midhun Malla¹, Aparna R Parikh²

Affiliations

¹ Section of Hematology/Oncology, West Virginia University School of Medicine, 1 Medical Center Drive, Morgantown, WV 26506, USA.
² Harvard Medical School, Massachusetts General Hospital Cancer Center, Tucker Gosnell Center for Gastrointestinal Malignancies, Termeer Center for Targeted Therapies, Boston, MA 02114, USA. Electronic address: Aparna.Parikh@mgh.harvard.edu.

PMID: 35577710
DOI: 10.1016/j.hoc.2022.02.009

Abstract

This review provides a high level overview of several applications of circulating tumor DNA (ctDNA) in colorectal cancer (CRC) patients. ctDNA has been shown to be a promising prognostic biomarker for detection of minimal residual disease, monitoring for early recurrence and response monitoring in metastatic disease. Prospective studies are ongoing to investigate the ability of ctDNA to inform clinical decision making. This article also reviews existing and emerging alterations in CRC and their respective therapeutic approaches.

Keywords: Circulating tumor DNA; Gene fusions; Minimal residual disease; Precision medicine; Response prediction; Targeted therapy.

Publication types

Review
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

MeSH terms

Biomarkers, Tumor / genetics
Circulating Tumor DNA* / genetics
Colorectal Neoplasms* / diagnosis
Colorectal Neoplasms* / drug therapy
Colorectal Neoplasms* / genetics
Humans
Neoplasm, Residual
Prospective Studies

Substances

Biomarkers, Tumor
Circulating Tumor DNA

Grants and funding

U54 GM104942/GM/NIGMS NIH HHS/United States